♟️ Friday 29 August 2025 Fri, 29 Aug 2025

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.

PARKD Limited reported a remarkable 218% increase in revenue to $11.83 million for FY25, driven by key construction projects and new licensing agreements. The company narrowed its loss by 74%, signaling progress in commercialising its modular construction technology.

Jatcorp Limited reported a $6.9 million net loss for FY25, hit by a trademark dispute in China that suspended key product sales. Despite setbacks, the company is accelerating new channel growth and product innovation to regain momentum.

Volt Group Limited reported a 24% revenue decline and a net loss of $271,854 for the half year ended June 2025, primarily due to timing delays in Wescone orders and iron ore sector shutdowns. Despite this, the company advances its innovative ATEN waste heat to power technology and expands its EcoQuip solar light tower fleet, while initiating a 12-month on-market share buy-back.

Vection Technologies reports its first positive underlying EBITDA alongside a 22% pro-forma revenue increase, driven by major defence contracts and AI integration. The company’s strategic acquisition and sector diversification set the stage for sustainable growth in FY26.

Mesoblast Limited marked a transformative year with FDA approval and commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, driving a 191% jump in cell therapy revenues. The company is now poised to expand its footprint in inflammatory diseases with multiple clinical trials and label extensions underway.

Visionflex Group Limited reported a sharp 33% decline in revenues and a 69% increase in net losses for FY25, with auditors flagging material uncertainty over the company’s ability to continue as a going concern.

Bapcor Limited reported a modest revenue decline and an 8.4% drop in pro-forma NPAT for FY25 amid significant business simplification and strategic initiatives aimed at sustainable growth.

Mesoblast reports a strong FY2025 financial performance driven by the commercial launch of Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in children. The company is advancing multiple clinical programs targeting inflammatory diseases, heart failure, and chronic low back pain.

Scalare Partners reports a 26% rise in FY25 revenue, driven by strong service demand and key acquisitions, including Inhouse Ventures and the pending Tank Stream Labs deal.

Scalare Partners Holdings Limited reported a 26% increase in total revenues to $3.54 million for FY25, driven by strong growth in founder support services and strategic acquisitions. However, the Group recorded a statutory loss of $2.65 million amid increased structural and compliance costs following its ASX listing and expansion.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

Bapcor Limited reported a decline in FY25 pro-forma net profit after tax by 8.4%, alongside a successful $170 million debt refinancing extending maturities to 2029-2031. The company declared a fully franked final dividend and announced significant board and executive changes.

NobleOak Life Limited reported robust FY25 results, with a 20% increase in in-force premiums and a 22% rise in underlying NPAT, underpinned by strategic investments in AI and a transition to a capital-efficient Life Company structure.

Island Pharmaceuticals reported a $3.92 million loss for FY2025 despite an 86% increase in income, with no dividends declared.

Regal Investment Fund reported a sharp 78% drop in operating profit for FY25 but maintained steady performance slightly above the RBA Cash Rate. The fund bolstered its position with a $104 million capital raise and extended its on-market buy-back program through mid-2026.

PEXA Group Limited reported a 16% revenue increase to $393.6 million for FY25, driven by growth across its Australian Exchange, UK International business, and Digital Solutions segments. Despite a statutory net loss of $76.1 million due to impairments and deferred tax derecognition, core EBITDA rose 21% with improved margins.

Sumitomo Corporation has committed to a strategic equity investment in Mitchell Services’ Loop Decarbonisation JV, valuing the business at $24 million and signaling confidence in its mining sector emissions solutions.

Metro Mining has delivered a striking half-year turnaround with a $119.8 million net profit, driven by record shipments, strong pricing, and significant foreign currency hedging gains.

Bhagwan Marine Limited has delivered a strong first year as an ASX-listed company with record net revenue and EBITDA growth, alongside its inaugural dividend declaration. The company is advancing growth in offshore energy, subsea, ports, and defence sectors while investing in innovation and fleet expansion.

Metro Mining Limited delivered a remarkable turnaround in the first half of 2025, posting record bauxite shipments and a $119.8 million net profit after tax, reversing prior losses and impairments.

Bhagwan Marine Limited has reported record financial results for FY25, driven by strong growth across its core marine services and new sectors. The company also declared its inaugural fully franked dividend, signaling confidence in its strategic direction.

PPK Group Limited reported a significant statutory loss for FY25, driven by a major non-cash impairment on its Li-S Energy investment, while its ballistic protection arm Craig International Ballistics delivered exceptional revenue growth.

Gumtree Australia Markets Limited reports a transformational FY25 marked by a $6.8 million Capital Markets division sale, a near doubling of EBITDA, and promising expansions in transactional services and partnerships.